Sign in
CompletedPhase 2

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

Key facts

Who runs it
University of Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
49 people enrolled
Started
22 Jun 2023
Ended
1 Jun 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tolcapone
  • Placebo
Record updated
23 September 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Men and women age 18-65 years
  • Primary diagnosis of OCD
  • YBOCS score of at least 21 at baseline (moderate or higher severity)
  • Ability to understand and sign the consent form

Who cannot take part

  • Use of any new psychotropic medication within 3 months of study entry (stable doses of psychotropics will be allowed)
  • Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
  • History of psychosis or bipolar disorder based on DSM-5 criteria
  • Alcohol/substance use disorder and/or illegal substance use based on urine toxicology
  • Major cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent
  • Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
  • Subjects considered an immediate suicide risk based on the Columbia Suicide Severity rating Scale (C-SSRS) (www.cssrs.columbia.edu/docs)
  • Initiation of psychological interventions within 3 months of screening (those who are continuing with CBT will be included)
  • Abnormal liver function tests at baseline
  • MADRS >30 at baseline

Where in United States

  • University of Chicago Medical CenterChicago, United States

About the trial

What the trial wants to find out

The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.

The 2 groups in the trial

  • TolcaponeTreatment being tested

    100mg of tolcapone twice daily for two weeks, then 200mg tolcapone twice daily for the remaining six weeks.

  • PlaceboPlacebo, for comparison

    100mg of placebo twice daily for two weeks, then 200mg of placebo twice daily for the remaining six weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Double-Blind, Randomized, Placebo-Controlled Study of Tolcapone for OCD
Record updated
23 September 2026